Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07634471 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 960
- Enrollment target
NCT07634471 is a Phase 2 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 960 participants.
The verdict
NCT07634471, a Phase 2 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 960 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Rituximab
- DRUG Bendamustine
- BIOLOGICAL MK-1045
- BIOLOGICAL Rituximab biosimilar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2026-06-22 |
| Est. Completion | 2035-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07634471
The ClinicalTrials.gov registry entry for NCT07634471 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07634471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07634471 about?
NCT07634471 is a clinical study titled "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)". Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type ...
What is the current status of trial NCT07634471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2026-06-22. Estimated completion is 2035-07-23.
What interventions are being tested in trial NCT07634471?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (BIOLOGICAL), Bendamustine (DRUG), MK-1045 (BIOLOGICAL), Rituximab biosimilar (BIOLOGICAL).
Who is sponsoring clinical trial NCT07634471?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.